| At NY Life Sci 2021, Yancopoulos, Dunn & More to Ponder NYC’s Bio Future | Ben Fidler | 10/19/16 | New York |
| Defying Patient Pressure, Anthem Says No to Sarepta’s Duchenne Drug | Ben Fidler | 10/07/16 | Boston |
| Selecta, Eyeing IPO, Brings Sanofi, Crossovers Aboard For $38M Round | Ben Fidler | 09/08/15 | Boston |
| In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer | Ben Fidler | 08/31/15 | New York |
| New CEO and $80M Later, Syndax Looks Prepped for Second IPO Try | Ben Fidler | 08/24/15 | Boston |
| WaVe Joins the Crossover Party With $66M Series B for RNA Drugs | Ben Fidler | 08/18/15 | Boston |
| East Coast Biotech Roundup: Editas, Checkmate, Ovid & More | Ben Fidler | 08/14/15 | Boston |
| Ovid Therapeutics Secures $75,000,000 Series B Financing | VentureDeal | 08/12/15 | New York |
| Ex-Teva CEO’s Brain Disease Startup, Ovid, Bags $75M From Crossovers | Ben Fidler | 08/11/15 | New York |
| Levin Steps in as Ovid CEO, Confirms Plan to Target Rare Neuro Diseases | Ben Fidler | 04/16/15 | New York |
| East Coast Biotech Roundup: Hemophilia, Levin, Vertex, Semma & More | Ben Fidler | 03/27/15 | Boston |
| Ex-Teva CEO Levin Is Back With Startup Aimed at Rare Neuro Disorders | Ben Fidler | 03/25/15 | New York |
